Jaw osteonecrosis (Medication‑related) - Symptoms, Causes, Treatment & Prevention

Overview

Medication‑related jaw osteonecrosis (MRONJ) is a serious condition in which the bone tissue of the jaw (maxilla or mandible) dies and fails to heal, usually after a minor dental procedure or spontaneously. The term was introduced by the American Association of Oral and Maxillofacial Surgeons (AAOMS) in 2014 to describe osteonecrosis specifically linked to the use of certain medications, most notably anti‑resorptive agents (e.g., bisphosphonates, denosumab) and anti‑angiogenic drugs (e.g., bevacizumab, sunitinib).

MRONJ most commonly affects adults over 50 who are receiving these drugs for conditions such as osteoporosis, metastatic bone disease, or multiple myeloma. Though the exact prevalence is difficult to determine because many cases go unreported, large population‑based studies estimate:
• Bisphosphonate‑related MRONJ occurs in 0.1–0.2 % of patients taking oral bisphosphonates for osteoporosis, but up to 1–9 % in cancer patients receiving high‑dose intravenous therapy.
• Denosumab‑related MRONJ appears in roughly 0.5 % of oncology patients and <0.01 % of those using the osteoporosis formulation (Prolia®).
These figures come from data compiled by the Mayo Clinic and the CDC.

Symptoms

Symptoms may develop weeks to months after drug exposure or a dental event. The clinical picture can be variable, but the following list captures the full spectrum reported in the literature.

• Exposed bone that does not heal within 8 weeks after gentle brushing.
• Pain or tenderness in the affected area—often described as dull, throbbing, or sharp when chewing.
• Swelling of the gums, lips, or face.
• Foul‑smelling discharge from the exposed bone or from a sinus tract.
• Redness (erythema) of the overlying mucosa.
• Loose teeth or feeling that a tooth is “floating.”
• Difficulty opening the mouth (trismus) due to muscle spasm or inflammation.
• Numbness or altered sensation (paraesthesia) in the lower lip or chin—rare but may indicate nerve involvement.
• Pathologic fracture of the jaw, often after minimal trauma.
• Secondary infection presenting with fever, chills, or lymphadenopathy.
• Weight loss or inability to eat in severe cases.

Early disease may be asymptomatic, discovered only on routine dental X‑rays. Prompt recognition of any exposed bone, especially in a patient on the implicated medications, is essential.

Causes and Risk Factors

MRONJ is not caused by a single factor; it results from an interplay between medication effects and local oral conditions.

Medications

• Anti‑resorptive agents
  • Intravenous nitrogen‑containing bisphosphonates (zoledronic acid, pamidronate) – highest risk.
  • Oral bisphosphonates (alendronate, risedronate, ibandronate) – lower risk but still relevant with long‑term use.
  • Denosumab (Xgeva® for cancer; Prolia® for osteoporosis).
• Anti‑angiogenic drugs (bevacizumab, sunitinib, sorafenib) – interfere with blood vessel formation needed for bone healing.
• Combination therapy – patients receiving both anti‑resorptive and anti‑angiogenic agents have a synergistically higher risk.

Patient‑related risk factors

• Duration of therapy > 2 years (especially IV bisphosphonates).
• Cumulative drug dose (higher total dose = higher risk).
• Cancer diagnosis with metastases to bone (breast, prostate, lung, multiple myeloma).
• Pre‑existing dental disease: chronic periodontitis, untreated caries, ill‑fitting dentures.
• Recent invasive dental procedures: extractions, implants, bone grafts, periodontal surgery.
• Smoking, diabetes, and corticosteroid use – impair wound healing.
• Concomitant radiation therapy to the head and neck (though this creates a separate entity, osteoradionecrosis, it adds to risk when anti‑resorptives are used).

Pathophysiology (simplified)

Anti‑resorptive drugs suppress osteoclast activity, leading to reduced bone turnover. Over time, micro‑damage accumulates and the jaw—subject to constant mechanical stress from chewing—fails to remodel. Anti‑angiogenic agents decrease blood supply, further compromising healing. When a tooth is extracted or an implant placed, the suppressed remodeling and reduced vascularity prevent normal bone repair, resulting in exposed necrotic bone.

Diagnosis

The diagnosis of MRONJ is primarily clinical, supported by imaging and a thorough medication history.

Diagnostic criteria (AAOMS, 2022)

1. Current or previous treatment with an anti‑resorptive or anti‑angiogenic medication.
2. Exposed bone or bone that can be probed through an intra‑oral or extra‑oral fistula in the maxillofacial region that persists for > 8 weeks.
3. No history of radiation therapy to the jaws or metastatic disease to the jawbones.

Diagnostic work‑up

• Clinical examination – inspection for exposed bone, palpation for tenderness, assessment of oral hygiene.
• Radiographs
  • Panoramic (OPG) X‑ray – useful for initial screening; may show radiolucent areas, sclerosis, or sequestra.
  • Cone‑beam CT (CBCT) – provides 3‑D detail of bone loss, cortical defects, and proximity to vital structures.
• Magnetic Resonance Imaging (MRI) – when soft‑tissue involvement or osteomyelitis is suspected.
• Laboratory tests – CBC, CRP, ESR to assess infection; serum calcium and vitamin D levels to rule out metabolic contributors.
• Biopsy – rarely needed; if performed, must be done with caution to avoid worsening the lesion.

Treatment Options

Management aims to control pain, halt disease progression, eradicate infection, and restore function. Treatment is staged according to disease severity (stages 0‑3 per AAOMS).

Conservative (Stage 0‑1)

• Oral hygiene protocol – soft toothbrush, chlorhexidine mouth rinse (0.12 %) twice daily.
• Analgesia – acetaminophen or NSAIDs (if not contraindicated).
• Antibiotics – systemic coverage for suspected infection (e.g., amoxicillin‑clavulanate 875/125 mg BID for 10‑14 days). For penicillin‑allergic patients, clindamycin 300 mg QID.
• Topical agents – doxycycline gel or chlorhexidine gel applied directly to exposed bone.

Moderate disease (Stage 2)

• All measures from Stage 1 plus:
  • Long‑term antibiotics (e.g., minocycline 100 mg BID) guided by culture & sensitivity.
  • Debridement/sequestrectomy – removal of necrotic bone under local or general anesthesia, preserving vital structures.
  • Adjunctive therapies –
    • Platelet‑rich plasma (PRP) or platelet‑rich fibrin (PRF) to promote healing.
    • Low‑level laser therapy (LLLT) for pain reduction and tissue regeneration.

Advanced disease (Stage 3)

• Comprehensive surgical resection may be required, sometimes combined with reconstruction using vascularized free flaps.
• Hospital‑based IV antibiotics (e.g., ceftriaxone + metronidazole) for osteomyelitis.
• Consider temporary discontinuation (drug holiday) of the anti‑resorptive after consulting the prescribing oncologist or endocrinologist; evidence for benefit is mixed but may be reasonable after 6–12 months of cessation.

Medication considerations

• Teriparatide (recombinant PTH 1‑34) – off‑label use in selected osteoporosis patients has shown accelerated healing in small studies (NIH, 2020).
• Bisphosphonate or denosumab substitution – switch to a less potent agent if ongoing therapy is essential.

Supportive care

• Nutrition counseling – soft‑diet recommendations, supplementation of calcium/vitamin D.
• Psychological support – chronic facial pain can affect quality of life.

Living with Jaw Osteonecrosis (Medication‑related)

Adapting daily habits can reduce discomfort and prevent disease progression.

• Oral hygiene – brush gently twice daily with a soft‑bristle brush; floss with a water flosser if traditional floss irritates the area.
• Diet – prioritize soft, nutrient‑dense foods (yogurt, smoothies, mashed potatoes). Avoid hard, crunchy, or sticky foods that could traumatize exposed bone.
• Dental follow‑up – schedule regular (every 3‑6 months) visits with a dentist knowledgeable about MRONJ.
• Smoking cessation – nicotine impairs blood flow; use nicotine replacement or counseling programs.
• Medication review – keep an up‑to‑date list of all drugs and share it with every dental and medical professional.
• Stress management – chronic pain can worsen stress; mindfulness, gentle exercise, and support groups are helpful.
• Emergency kit – have a small supply of chlorhexidine rinse and prescribed antibiotics on hand if sudden swelling occurs.

Prevention

Prevention focuses on dental assessment before starting high‑risk medications and meticulous oral care thereafter.

1. Baseline dental evaluation – complete oral exam, necessary extractions, and treatment of periodontal disease before initiating bisphosphonate or denosumab therapy.
2. Delay elective invasive procedures – whenever possible, complete extractions or implants at least 2 weeks before beginning anti‑resorptives.
3. Maintain excellent oral hygiene – fluoride toothpaste, antiseptic rinses, regular professional cleanings.
4. Modify drug regimens only under specialist guidance – drug holidays may be considered for patients on long‑term oral bisphosphonates who need invasive dental work.
5. Educate patients – provide written material about signs of MRONJ and emphasize prompt reporting of any oral sore or exposure.
6. Control systemic risk factors – manage diabetes, encourage smoking cessation, and ensure adequate nutrition.

Complications

If left untreated or inadequately managed, MRONJ can lead to serious outcomes:

• Chronic infection and osteomyelitis – may spread to adjacent soft tissues or the cervical spine.
• Pathologic fractures – can cause severe pain, malocclusion, and require complex reconstructive surgery.
• Fistula formation – communication between the oral cavity and the skin (oro‑cutaneous) or sinus cavities.
• Sepsis – especially in immunocompromised cancer patients.
• Significant impairment of nutrition – leading to weight loss, hypoalbuminemia, and decreased treatment tolerance for the underlying disease.
• Reduced quality of life – chronic pain, facial disfigurement, and psychological distress.

When to Seek Emergency Care

---

References:

• American Association of Oral and Maxillofacial Surgeons. “AAOMS Position Paper on Medication‑Related Osteonecrosis of the Jaw.” 2022. aaoms.org
• Mayo Clinic. “Bisphosphonate Side Effects.” Updated 2023. mayo clinic.org
• Cleveland Clinic. “Medication‑Related Osteonecrosis of the Jaw (MRONJ).” 2022. clevelandclinic.org
• National Institutes of Health. “Denosumab and Osteonecrosis of the Jaw.” 2020. nih.gov
• World Health Organization. “Guidelines for the Management of Cancer‑Related Bone Disease.” 2021. who.int
• Ruggiero SL, et al. “Medication‑Related Osteonecrosis of the Jaw: A Review of Current Concepts.” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology* 2021;132(4):404‑416.